-
New nanoElute 2 offers nano-LC advancement, supports automated single-cell sample preparation of label-free ProteoCHIP on CellenONE platform
-
MetaboScape® 2023 Advances Fluxomics Applications and Ion Mobility Offset Mass Alignment (‘MOMA’) Events for High-Throughput 4D Metabolomics
-
Advances in MALDI HiPLEX-IHC™ workflows and in PaSER™ on-the-fly intelligent acquisition software for 4D Metaproteomics
MAASTRICHT, Netherlands, August 29, 2022–(BUSINESS WIRE)–At the International Mass Spectrometry Conference (IMSC 2022), Bruker Corporation (Nasdaq: BRKR) today announced the launch of the new nanoElute® 2 nano-LC, from MetaboScape® and TASQ® 2023 software that fluxomics supports , and the latest advances in the intelligent acquisition of PaSER™ to advance protein-protein interaction (PPIs) research and metaproteomics applications.
This press release contains multimedia. Watch the full release here: https://www.businesswire.com/news/home/2020829005210/en/
The nanoElute® 2, a high performance nanoflow liquid chromatography system with an intuitive and flexible user interface, covering a wide range of applications from single-cell to routine high-throughput proteomics (Photo: Business Wire)
The next generation nanoElute® 2 combines excellent nano-LC chromatography performance with hardened high-pressure diverter valves and finger-tight torque-limiting capillaries for leak-free connections with no dead volume, without the risk of over-tightening or damaging capillaries. The nanoElute 2 features a further improved nano-LC pump design and an intuitive and flexible user interface that covers a wide range of applications from single-cell proteomics to plasma proteomics. The nanoElute 2 now also supports the label-free ProteoCHIP® for the CellenONE platform for highly sensitive single-cell proteomics.
dr. Henrik JohanssonSenior Scientist in Cancer Proteomics in the Department of Oncology-Pathology at the Karolinska Institute in Sweden, said: “The ‘solve’ workflow on the nanoElute 2 now perfectly supports our proteomics sample preparation done by the robotic platform in 96 or 384-well plates. The nanoElute 2 dissolves the tryptic peptides directly in the plate prior to injection, avoiding manual intervention and thus streamlining our workflows.”
The last MetaboScape 2023 release provides streamlined collision cross-section (CCS)-enabled metabolic profiling and annotation workflows for 4D timsTOF data acquisition to highly reliable annotations for lipids and metabolites. New features include improved 4D peak detection and integration, accelerated processing, and smart merging of positive and negative ion data. Powerful automated prediction of CCS values from chemical structures in spectral libraries takes advantage of the accurate CCS values measured on the timsTOF.
To support the metabolomics community’s focus on quality, MetaboScape 2023 now provides better tools for assessing data quality in large-scale studies, while TASQ 2023 extends target screening and quantification through CCS-enabled MOMA events. Finally, refinements to stable isotope labeling methods simplify large-scale labeling experiments.
Professor Nils FaergemanDepartment of Biochemistry and Molecular Biology at the University of Southern Denmark, commented: “The new TASQ fluxomics workflow streamlined our stable isotope labeling experiments on our timsTOF instrument. The integrated natural abundance correction and fractional enrichment calculations, along with manual assessment capabilities, allow us to confidently generate results for our small molecule isotope tracing studies.”
At IMSC Buker also shows the new MALDI HiPLEX-IHC workflow for multiplex imaging of protein targets. MALDI HiPLEX-IHC combines Bruker’s IntelliSlides® automated MALDI workflow with AmberGen’s Miralys antibody-based photocleavable mass tags for spatial localization of target proteins across tissue sections. Key benefits of the workflow include whole slide field of view and multiplexing capability of tens to over a hundred protein targets from FFPE or freshly frozen tissue sections, as well as multiomics ability to overlap metabolite, lipid, and glycan mass specification images with protein targets from the same section.
dr. Ron HeerenDistinguished Professor and Limburg co-chair of the Maastricht Multimodal Molecular Imaging (M4I) Institute, added: “At M4I, we are developing workflows and techniques to contextualize the role of individual cells in disease and determine how interactions between cells affect cellular states locally. influence and over long distances. MALDI HiPLEX-IHC provides a seamless platform for integrating protein expression information into key projects we collaborate on with our experimental pathology team.”
At IMSC, Bruker is also enhancing its bioinformatics proteomics real-time search capabilities using PaSER™. Intelligent instrument control utilizing the 4e dimension of large-scale accurate CCS data promises significantly more insights, from post-translational modifications of the epiproteome to substoichiometric analytes in targeted approaches.
dr. Mathieu Lavallée-Adamassociate professor at the University of Ottawa and the Ottawa Institute of Systems Biology in Ottawa, Canada, said, “We are using machine learning, such as Bayesian inference, artificial neural networks, and logistic regression classifications, with large-scale proteomics data to gain biological knowledge about cellular mechanisms and disease processes Biological samples are often sample-limited, requiring as much information as possible to be extracted in separate analyses, now complemented by on-the-fly adjustments of mass spectrometry parameters Bruker’s intelligent feedback control via PaSER allows us to quickly prototype on feedback-based bioinformatics modules for community use. We are excited to collaborate with Bruker on further feedback-based intelligent acquisition for the study of protein-protein interactions and metaproteomics.”
About Bruker Corporation (Nasdaq: BRKR)
Bruker enables scientists to make groundbreaking discoveries and develop new applications that improve the quality of human life. Bruker’s state-of-the-art scientific instruments and state-of-the-art analytical and diagnostic solutions enable scientists to investigate life and materials at the molecular, cellular and microscopic levels. Working closely with our customers, Bruker enables innovation, improved productivity and customer success in bioscience molecular and cell biology research, in applied and pharmaceutical applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-performance life science and diagnostic systems and solutions in preclinical imaging, clinical phenomics, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. Go to www.bruker.com.
Check out the source version at businesswire.com: https://www.businesswire.com/news/home/2020829005210/en/
Contacts
Media
Petra Scheffer
Bruker Daltonics Marketing Communication
T: +49 (421) 2205-2843
E: petra.scheffer@bruker.com
Investor Relations
Justin Ward
sr. Director Investor Relations & Corp Development
T: +1 (978) 663-3660, extension no. 1479
E: Investor.Relations@bruker.com
